They’re getting implanted in a less invasive way, and they’re getting better at mimicking the actual structure of the heart. Welcome to the world of next-generation heart valve replacement.
Join us on May 4, 2026, at our DeviceTalks Minnesota event at the University of Minnesota for our panel, “Engineering the Next Generation of Heart Valves.” We’ll explore the science and discuss the business strategy behind the space.
Panelists will include five next-generation heart valve replacement companies that are especially generating buzz in the space:
1. Anteris Technologies
Publicly traded on the Nasdaq and in Australia where it was founded, Anteris has a significant presence outside of Minneapolis in Eagan. Anteris’ DurAVR is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. Medtronic made a $90 million strategic investment in Anteris early this year. Hear from Anteris Technologies CEO Wayne Paterson at DeviceTalks Minnesota.
2. CroíValve
Doctors in Poland recently completed the first transcatheter treatment of tricuspid regurgitation (TR) using the CroíValve Duo Adapt system. Ireland-based CroiValve’s Duo is anchored in a novel way: A support catheter anchored to a stent in the superior vena cava secures the valve across the annulus. The anchor system leaves the right heart and native valve apparatus untouched. Find out more from Gavin Kenny, CoiValve’s VP of R&D, at DeviceTalks Minnesota.
3. Foldax
Salt Lake City–based Foldax designed its Tria mitral valve to accommodate the anatomy and pressures of the mitral position. It combines the company’s proprietary LifePolymer with a valve design for resisting calcification. The company says its valve withstands stresses and strains without failure, restoring quality of life without lifelong anticoagulant use. Foldax launched Tria in India last year. We’ll have Ryan Stanfield, VP of engineering and operations at Foldax, at DeviceTalks Minnesota.
4. Laplace Interventional
5. TriCares
Munich, Germany–based TriCares’ Topaz is a transcatheter tricuspid valve replacement system featuring a unique dual-stent design and two valve sizes. It can fit into a low-profile catheter system. TriCares, which also operates out of Paris and Minneapolis, announced earlier this month that it received FDA investigational device exemption (IDE) to study Topaz.
Find out more about DeviceTalks Minnesota and register here.
Want to find out even more about next-gen heart valve replacement? Download our free MassDevice Transcatheter Heart Valves Special Report.
